Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Xue X, Hall MD, Zhang Q, Wang PC, Gottesman MM, Liang XJ. Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano. 2013 Dec 23; 7(12):10452-64.

View in: PubMed

authors with profiles

Paul Wang

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support